HOUSTON, Feb. 19, 2014 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences.
Greg Browne, Cyberonics' Chief Financial Officer, will participate in one-on-one meetings with investors during the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, February 25, 2014. No formal presentation is scheduled, and the one-on-one meetings will not be webcast.
Mr. Browne will participate in the neuromodulation panel discussion at the Citi 2014 Global Healthcare Conference in New York on Wednesday, February 26, 2014 at 9:40 AM Eastern Time. This panel discussion will not be webcast.
Dan Moore, Cyberonics' President & Chief Executive Officer, will present at the Barclays Global Healthcare Conference in Miami on Tuesday, March 11, 2014 at 2:30 PM Eastern Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on March 11, 2014.About Cyberonics, Inc. and the VNS Therapy ® System Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide. Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com . Contact Information Greg Browne, CFOCyberonics, Inc.100 Cyberonics Blvd., Houston, TX 77058Main: (281) 228-7262 / Fax: (281) 218-9332 email@example.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts